Psilocybin Side Effects and Safety

The honest clinical-safety profile of supervised psilocybin-assisted therapy: most side effects are transient and resolve over the dosing day or within the following 24 hours — mild nausea, transient blood-pressure elevation, headache, fatigue afterward, and the experiential intensity itself (which can include challenging moments often called "challenging experiences" in the clinical literature). Serious adverse events in published trials have been rare. Long-term safety data is limited but encouraging — the Agin-Liebes 2020 follow-up of the Ross cohort at 4–5 years did not surface persistent harms. Several specific drug interactions and contraindications matter: lithium is an absolute contraindication (seizure case reports); MAOIs (monoamine oxidase inhibitors) are typically excluded; high-dose SSRIs (selective serotonin reuptake inhibitors) may attenuate the experience and theoretically raise serotonin syndrome risk; tramadol carries serotonin syndrome concern. Psychiatric exclusions are firm: personal history of psychotic disorder, first-degree family history of psychotic disorder, active mania or recent hypomania, and active substance use disorder requiring treatment. Hallucinogen Persisting Perception Disorder (HPPD — persistent visual disturbances after psychedelic use) is rare in clinical settings and typically self-limiting. This article walks through the safety profile honestly without minimizing real concerns or overstating them.

Key takeaways

• Acute side effects during/after a session: mild-to-moderate nausea (~50% of participants in trials), transient blood pressure and heart rate elevation, mild headache, fatigue, anxiety surges or "challenging experiences." Most resolve within hours.
• Long-term safety at therapeutic supervised doses: no persistent harms documented at scale in published trials. Agin-Liebes 2020 4–5 year follow-up of the Ross cancer cohort found no late-emerging psychiatric or medical concerns.
• Absolute contraindications: personal history of psychotic disorder, first-degree family history of psychotic disorder, active mania or recent hypomania, uncontrolled cardiovascular disease, current pregnancy, concurrent lithium (seizure case reports).
• Drug interactions: high-dose SSRIs/SNRIs may attenuate effect (theoretical serotonin syndrome at high doses); MAOIs typically excluded; tramadol carries serotonin syndrome concern; benzodiazepines may attenuate.
• Challenging experiences during dosing — fear, grief, body horror — are common and managed by the therapy team; integration sessions process them. They are not failures and rarely produce lasting harm.
• Hallucinogen Persisting Perception Disorder (HPPD) is rare in clinical settings and typically self-limiting. Most case reports involve recreational chronic use.
• Suicide risk in trials has not been a major concern at therapeutic supervised doses; in fact, several trials show acute suicidal-ideation reduction.
• The clinical-recreational distinction matters here as it does for ketamine: supervised therapeutic psilocybin has a fundamentally different safety profile than recreational chronic high-dose use.

Acute side effects — what to expect during and after the session

Nausea and gastrointestinal

Mild-to-moderate nausea is reported in roughly 50% of psilocybin sessions in published trials, especially during onset. Some protocols use pre-dose anti-emetics (ondansetron is common); some recommend light fasting that morning to reduce risk. Nausea usually resolves over 1–2 hours and rarely persists beyond the dosing day.

Cardiovascular — transient BP and HR elevation

Psilocybin acutely elevates sympathetic tone. Blood pressure and heart rate typically rise during dosing — often by 10–20% from baseline — and return to baseline within 1–2 hours of comedown. This is why pre-treatment cardiovascular screening matters: uncontrolled hypertension, recent MI (within 6 months), severe structural heart disease, and significant arrhythmia are absolute or relative contraindications. Well-controlled hypertension on appropriate medication is generally compatible.

Headache

Mild-to-moderate headache during the experience or in the hours afterward is common. Usually responds to rest, hydration, and standard analgesia. Persistent severe headache should be flagged.

Anxiety and challenging experiences

A meaningful percentage of sessions include moments of intense fear, grief, body horror, or disorientation. The clinical literature reframes these from "bad trips" to "challenging experiences" — and they are often where therapeutic content emerges.

Carbonaro et al. 2016, J Psychopharmacology surveyed psilocybin users about challenging experiences and found that most resolved without lasting harm; many participants reported positive long-term outcomes following challenging experiences when supported by adequate set/setting and integration. The Hartogsohn 2016 set/setting framework establishes that environmental and relational context heavily modulate how challenging content is experienced and integrated.

The clinical practice: therapy team practices non-directive presence during peak intensity, supports grounding when needed, and uses integration sessions afterward to process challenging content. Most challenging experiences become productive parts of the therapeutic work.

Fatigue afterward

Most patients feel emotionally and physically fatigued for 24–48 hours after dosing. This is normal and reflects the intensity of the experience.

Visual after-effects

Mild visual after-effects (slightly enhanced colour, occasional brief afterimages) sometimes persist for hours-to-days after dosing. Persistent visual disturbances are rare in clinical settings — see HPPD framing below.

Long-term safety considerations

The honest framing: long-term safety data at therapeutic supervised doses is limited but encouraging. The largest published long-term follow-up is Agin-Liebes et al. 2020, J Psychopharmacology — 4–5 year follow-up of the Ross 2016 NYU cancer cohort. Findings:

• 60–80% maintained therapeutic response at 4–5 years.
• Participants overwhelmingly rated the experience as among the most meaningful of their lives.
• No late-emerging psychiatric or medical concerns reported.
• No cases of HPPD, persistent psychosis, or substance use disorder emerging.

Other trial follow-ups (Carhart-Harris 2018 6-month TRD follow-up; Davis 2021 1-year follow-up) similarly did not surface persistent harms. The Bogenschutz 2022 AUD trial reported sustained benefits without late-emerging concerns over 32 weeks.

Limitations of the long-term data: sample sizes are small relative to long-term ketamine data (Wajs 2020 SUSTAIN-2 N=802 over 1 year); most published trials are research populations with screened-out psychiatric history; multi-year observational data in real-world SAP-pathway populations is nascent.

The clinical-recreational distinction matters: most published concerns about long-term psilocybin harm derive from recreational chronic high-dose use, not therapeutic supervised single-or-two-dose protocols.

Drug interactions — the meaningful ones

Absolute / strongly contraindicated

• Lithium: case reports describe seizures with concurrent lithium and psilocybin. Most clinical protocols treat lithium as an absolute contraindication; patients on lithium who pursue psilocybin SAP do so only after carefully managed taper under prescriber supervision, if at all.
• MAOIs (monoamine oxidase inhibitors): theoretical risk of serotonergic crisis. Typically excluded from clinical psilocybin work.
• Tramadol: carries serotonin syndrome risk with serotonergic agents; flagged as a meaningful interaction in clinical screening.

Relative — may attenuate or interact

• High-dose SSRIs/SNRIs: may attenuate the psychedelic experience (chronic SSRI use can blunt psilocybin's effects through 5-HT2A receptor adaptation). Theoretical serotonin syndrome risk is real but rare at clinical doses. Many trial protocols taper SSRIs before dosing under prescriber supervision; some protocols hold them on dosing day; some continue them at lower doses. Specific approach is individualized.
• Benzodiazepines: may attenuate psilocybin's effect (similar to the documented attenuation of ketamine's antidepressant effect by high-dose benzos). Many protocols hold benzodiazepines on dosing day.
• Lamotrigine: limited data; sometimes flagged because of seizure-context concerns, though the lithium concern is more established.

Generally compatible

• Atypical antipsychotics (low dose; for mood stabilization) — generally compatible, though they can attenuate the psychedelic experience through 5-HT2A antagonism.
• Standard cardiovascular medications (well-controlled hypertension, statins) — generally compatible with appropriate cardiac screening.
• Gabapentin, pregabalin — generally compatible.
• Standard pain medications excluding tramadol — opioids generally compatible at standard doses; tramadol specifically flagged.

The honest summary: most psychiatric medications can be navigated around psilocybin therapy, but lithium and MAOIs are firm exclusions; SSRIs require taper planning; tramadol carries specific concern. ATMA CENA's intake call coordinates with your prescribing physician on medication review.

Psychiatric and medical exclusions

Absolute contraindications

• Personal history of psychotic disorder — schizophrenia, schizoaffective disorder, bipolar I disorder
• First-degree family history of psychotic disorder — more conservative exclusion adopted by most clinical protocols
• Active mania or recent hypomania (typically within 3 months)
• Active suicidal ideation requiring acute psychiatric care (note: this is different from background suicidal ideation in TRD, which has not emerged as a contraindication)
• Uncontrolled cardiovascular disease: severe structural heart disease, recent MI (within 6 months), unstable angina, significant arrhythmia
• Current pregnancy
• Concurrent lithium (seizure case reports)
• Anaphylaxis to psilocybin or related agents (extremely rare)

Relative contraindications

• Severe personality disorder with marked instability
• Complex trauma without adequate therapeutic alliance and prep capacity
• Active substance use disorder requiring stabilization first
• Cognitive impairment that interferes with informed consent
• Concurrent serotonergic medications at high doses
• Tramadol specifically

For the broader eligibility framework, see How to Access Psilocybin Therapy in Canada.

Hallucinogen Persisting Perception Disorder (HPPD)

HPPD is a rare condition involving persistent visual disturbances (visual snow, geometric patterns, palinopsia) lasting weeks-to-months after psychedelic use. The clinical reality:

• HPPD is rare in clinical/SAP-pathway settings. Published trials have not surfaced HPPD as a significant concern.
• Most case reports involve recreational chronic high-dose use, often combined with other psychedelics or cannabis.
• HPPD is typically self-limiting — most cases resolve without specific treatment over months.
• Risk factors appear to include heavy chronic use, polysubstance use (particularly cannabis), and possibly underlying anxiety vulnerability.

Patients reporting persistent visual changes more than 1 week after a psilocybin session should consult their prescribing physician.

Suicide risk — the surprising finding

Across published psilocybin trials, suicide risk has not been a major concern at therapeutic supervised doses. In several trials (Davis 2021 in MDD; Carhart-Harris 2016 in TRD; Goodwin 2022 in TRD), psilocybin was associated with acute reductions in suicidal ideation measured on standard scales — similar to the rapid-SI-reduction effect documented for ketamine (Grunebaum 2018 Am J Psychiatry).

The honest framing: this is encouraging but not a clinical claim of "psilocybin treats suicidality" — the evidence is secondary-outcome data within trials selected for inclusion criteria that exclude acute crisis. Active suicidal ideation requiring crisis intervention is best stabilized through standard psychiatric pathways before any psilocybin work.

What to flag urgently after a session

Most post-session symptoms resolve within 24–48 hours. The following warrant urgent contact with your prescribing physician or emergency services:

• Persistent disorientation or confusion more than 4–6 hours after session end
• Sustained elevated blood pressure (e.g., ≥160/100 mmHg) not resolving 1–2 hours after session
• Severe headache not controlled by rest, hydration, or routine analgesia
• Chest pain, shortness of breath, palpitations
• Severe persistent nausea or vomiting preventing oral intake more than 6 hours
• Worsening mood or new/worsening suicidal ideation in the 24–72 hours after session
• Persistent visual disturbances lasting more than a week (HPPD context)
• Persistent severe anxiety not resolving within 48 hours

For acute psychiatric crisis, call 9-8-8 (Canada Suicide Crisis Helpline) or go to your nearest emergency department.

The clinical-recreational distinction

Therapeutic supervised psilocybin has a fundamentally different safety profile than recreational chronic high-dose use:

The honest framing: most safety concerns documented in older literature reflect recreational patterns. Therapeutic supervised single-dose protocols have a substantially different profile.

Frequently asked questions

Is psilocybin therapy safe? At therapeutic supervised single-dose protocols with appropriate pre-treatment screening, the safety profile is well-characterized: most side effects are transient and resolve within hours-to-days. Serious adverse events in published trials have been rare. Long-term data is limited but encouraging.

What are the most common side effects? Mild-to-moderate nausea, transient blood pressure elevation, mild headache, fatigue, and the experiential intensity itself (which can include challenging moments). Most resolve within the dosing day or 24 hours afterward.

Can I take psilocybin if I'm on an SSRI? This is a clinical decision with the prescribing physician. Many trial protocols taper SSRIs before dosing under supervision. Some clinical models continue lower-dose SSRI through dosing. Specific approach is individualized.

Can I take psilocybin if I'm on lithium? Generally no — concurrent lithium is treated as an absolute contraindication due to seizure case reports. Patients on lithium pursuing psilocybin SAP do so only after carefully managed taper under prescriber supervision, if at all.

What about benzodiazepines? Benzodiazepines may attenuate psilocybin's effect. Many protocols hold benzodiazepines on dosing day; not always a hard exclusion but a meaningful pharmacodynamic consideration.

What about tramadol? Tramadol carries serotonin syndrome risk with psilocybin and is flagged as a meaningful interaction. Discuss with your prescribing physician and pain provider before psilocybin work.

What if I have a difficult experience? Difficult experiences (fear, grief, body horror, disorientation) are common and often productive. The therapy team holds non-directive presence; integration sessions are where challenging content becomes meaningful. Most challenging experiences resolve with appropriate set/setting and integration.

Is HPPD a real risk? HPPD is rare in clinical/SAP-pathway settings. Most case reports involve recreational chronic use, often polysubstance. HPPD is typically self-limiting.

Will psilocybin trigger psychosis? Personal history of psychotic disorder and first-degree family history are absolute contraindications precisely because of this concern. In screened populations without these risk factors, psychosis emerging from clinical psilocybin therapy has been very rare across published trials.

Will I become addicted? Psilocybin has very low abuse potential — substantially lower than most controlled substances. The single-or-two-dose clinical protocol does not create exposure conditions associated with dependence. SAP regulatory framework does not allow take-home dispensing.

What if I have heart disease? Pre-treatment cardiovascular screening is essential. Recent MI, severe structural heart disease, unstable angina, and significant arrhythmia are absolute contraindications. Well-controlled hypertension on medication is generally compatible.

What about cancer-related anxiety in a patient with cardiovascular comorbidity? Common scenario in palliative-care contexts. Cardiology consultation and risk-benefit weighing in coordination with the palliative-care team and prescribing physician is the appropriate pathway.

Sources

1. Carbonaro TM, et al. (2016). Survey of challenging experiences with psilocybin. J Psychopharmacol. https://pubmed.ncbi.nlm.nih.gov/27578767/
2. Agin-Liebes GI, et al. (2020). Long-term follow-up of psilocybin-assisted psychotherapy. J Psychopharmacol. https://pubmed.ncbi.nlm.nih.gov/31916890/
3. Carhart-Harris RL, et al. (2018). Psilocybin with psychological support for TRD: 6-month follow-up. Psychopharmacology. https://pubmed.ncbi.nlm.nih.gov/29119217/
4. Davis AK, et al. (2021). Psilocybin-assisted therapy for MDD: RCT. JAMA Psychiatry. https://pubmed.ncbi.nlm.nih.gov/33146667/
5. Goodwin GM, et al. (2022). COMP360 psilocybin in TRD Phase 2b. NEJM. https://pubmed.ncbi.nlm.nih.gov/36322843/
6. Bogenschutz MP, et al. (2022). Psilocybin-assisted therapy for AUD. JAMA Psychiatry. https://jamanetwork.com/journals/jamapsychiatry/fullarticle/2795625
7. Grunebaum MF, et al. (2018). Ketamine for rapid reduction of suicidal ideation — comparison context. Am J Psychiatry. https://pubmed.ncbi.nlm.nih.gov/29202575/
8. Government of Canada — 9-8-8 Suicide Crisis Helpline: https://988.ca/
9. Health Canada — SAP psychedelic-assisted psychotherapy: https://www.canada.ca/en/health-canada/services/drugs-health-products/drug-products/announcements/requests-special-access-program-psychedelic-assisted-psychotherapy.html

Related articles

• Psilocybin Therapy in Canada
• What Is Psilocybin Therapy?
• What to Expect at a Psilocybin Session
• How Psilocybin-Assisted Psychotherapy Works
• How to Access Psilocybin Therapy in Canada (SAP)
• Microdosing Psilocybin
• Ketamine Therapy Side Effects

Last updated: 2026-05-06